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-
power: weight ratio to run a 4-minute mile at Johannesburg's
altitude of 5,784 feet above sea-level. In deciding whether the
athlete is capable of running at the speed required for a
sufficient time, the extent of anaerobic metabolism he may incur
must also be considered. Details of such findings are given.
At sea-level the maximum oxygen intake would increase
by about 12% on average and oxygen consumption at the
different speeds would decrease so that the percentage of the
maximum the athlete would use when running at 15 m.p.h. at
the coast would be reduced markedly and he would run in
les anaerobic metabolism.
The results how how a scientific assessment can be made
of an athlete's ability to achieve world-class times in endurance
running and are suggested as an aid in the selection of athletes
for competition in international events. This would be con-
iderably less expensive than sending large teams of athletes
that are selected on the present hit-and-miss basis.
We wish to tbank Dr C. G. Williams, now of the University
of Cape Town, and Mrs M. J. von Rahden for their assi tance
in carrying out these studies; and the athletes concerned for
their willing co-operation. The Sugar Association of South
Africa defrayed certain expenses through its research funds.
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PRELIMINARY TRIAL OF A POWERFUL NEW SULPHONYLUREA IN MATURITY·ONSET
DIABETES-HB419 (GLffiENCLAMIDE)*
W. P. u. JACKSO , M.A., M.D., ER.C.P. AND A. 1. VINIK, M.B., B.CH., F.c.P. (S.A.), Diabetes Clinic, Groote
Schwu Hospital and the Department of Medicine, University of Cape Town
We have several sulphonylureas from which to choose in
the treatment of maturity-onset diabetes. They all act by
stimulating insulin output from the subjects' own pan-
creatic beta cells. It is thus extremely unlikely that a new
sulphonylurea will be found to be effective in a large
proportion of patients when others have failed, though
certainly some are more powerful than others--chlorpropa-
mide is more effective than tolbutamide in some indi-
viduals-and the reason for even this limited difference in
effectiveness is incompletely resolved. For a new sul-
phonylurea to be justifiably placed on the market it must
therefore fulfil several criteria:
1. It must be at least as effective as the most powerful
existing drugs.
2. It must be virtually non-toxic.
3. It must be acceptable by reason of few and minor
side-effects.
4. It should not be liable to produce serious hypogly-
caemia when correctly used.
The compound HB419, glibenclamide, is a sulphonyl-
urea with a long side-chain. Chemically, it is - { 4-(,8[2-
methoxy-5-chlorobenzamidoJ-ethyl)-benzosulfonyl } -N'-cy-





Fig. 1. Structural formula of glibenclamide.
This drug is quite remarkably powerful on a weight
basis, being approximately 500 times as potent as tolbuta-
'Date received: 19 February 1969.
mide and at least 50 times as potent as chlorpropa-
mide.'" This does not necessarily mean that it will be
more effective in the treatment of diabetes, but certainly
a far smaller dose is required, and this fact might reason-
ably be expected to reduce or abolish some of the toxic
effects pertaining to standard doses of other sulphonyl-
ureas. In fact, toxicity studies by the makers have indi-
cated that although the new side-chain has rendered this
sulphonylurea much more potent it has not rendered it
more toxic, weight for weight, than previous drugs of the
same class.'" In view of the very much smaller dose re-
quired, HB419 should therefore prove to be virtually safe,
except of course that it will occasionally produce hypo-
glycaemia. It has no antibacterial properties.
The duration of effective action of HB419 is reported
as being longer than that of tolbutamide, about 8 hours
after a 5-mg. dose, or over 12 hours with larger doses.'-3
It is reasonable to suppose that a single daily dose will
prove adequate to control the majority of sensitive dia-
betics.
Each tablet of HB4l9 contains 5 mg. Because of the
inherent safety of the drug there is no particular maxi-
mum dose level, but more than 4 tablets a day are be-
lieved to be wasteful, while it is probable that more than
2 will seldom be necessary.
A small preliminary trial of this drug, ending April
1968, wa carried out in Cape Town.
MATERIAL AND METHODS
Subjects
In the Diabetes Clinic of Groote Sehuur Hospital we
used HB419 in 34 diabetics on an outpatient basis. We
chose only maturity-onset diabetics, who had all failed
to be controlled on diet alone, and who were all re-
ceiving other tablets or insulin (one case) at the start of
the trial. There were no 'new' cases-most had had dia-
In a few cases it was possible to test the effect of taking
the daily requirement of tablets together in one dose. The
recommended time for single-dose therapy was midday,
because breakfast is generally a small meal. In 2 instances
tablets taken together did not produce as good a control
as when taken separately. .
There were 9 patients whose diabetes was of over 10
years' duration. Two achieved excellent control with
HB419-in one case only after the addition of metformin:
2 achieved good control and 4 failed.
Combination with Diguanides'
In 17 cases-i.e. exactly one-half the total subjects-
it was necessary to add a diguanide to the HB419 in an
attempt to improve control. The diguanide used was phen-
formin (Insoral TD) in 15 cases, 2 or 3 capsules daily,
and metformin (Glucophage) in 2 cases. Final results of
combined therapy were 4 failed, 5 fair, 4 good and
4 excellent.
One White woman, aged 65 years, had mild ischaemic
heart disease and diabetes that had been present for more
than 10 years. Five different sulphonylureas, including
HB419, produced no more than a poor 'fair' response.
The addition of metformin, 3 tablets daily, to 4 HB419
tablets led to an 'excellent' response.
Toxic EfJects
There were no toxic effects to HB419. Side-effects were
few. One patient complained of headache, and one of
fatigue and abdominal pain which did not necessitate
stopping the HB419~the relationship of these complaints
to the tablets was considered doubtful. (See case 2, below.)
No significant effect in 34 cases was noted on haemo-
globin, total white cell count, platelet count, serum bili-
rubin levels, alkaline phosphatase, SGOT or cholesterol.
In 8 cases no effect was seen on blood-urea levels, serum
sodium, potassium, chloride, uric acid, thymol turbidity,
zinc sulphate test, total proteins or albumin level. In 3
cases the serum amylase levels remained virtually un-
changed.
In addition no significant change was seen in body-
weight. Hypoglycaemic symptoms were not encountered.
Proteinuria was not seen unless already present.






















HB419TABLE J. CONTROL OF PATIENTS 0
Degree of cOIl/ro/
'Good' after tolbutamide failed .
'Excellent' after tolbutamide failed.
'Excellent' equal to tolbutamide .
'Fair' equal to tolbutamide
'Excellent' equal to cWorpropamide
'Good' equal to chlorpropamide .
'Excellent' better than chlorpropamide .
'Good' better than chlorpropamide
'Fair' better than chlorpropamide
'Fair' equal to chlorpropamide
'Excellent' after glymidine failed
'Good' better than glyrnidine ......
'Failed' equal to cWorpropamide
'Fair' better than diguanide alone ...
'ExceIlent' after poor on insulin
'Excellent' also on no tablets
Total 'ExceIlent' on HB419
Total 'Good' on HB4l9 ....
Total 'Fair' on HB4l9
Total 'Failed' on HB419
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betes between 5 and 10 years. We also tried to avoid
obese subjects; although 12 of our 34 were more than 5%
overweight by Broca's index, only 2 were more than
15% overweight. No patients with severe complicating di-
sease were included, though a few had well-compensated
heart disease.
Our 34 subjects included 10 men and 24 women; there
were 21 White and 13 non-White patients, with an age
range of 30 - 80 years.
Methods
Patients already taking tolbutamide or glymidine were
first tried on I tablet of HB419 daily; patients on chlor-
propamide were started on the same number of tablets
that they were already taking. Patients already taking a
diguanide in addition to sulphonylurea were usually kept
on the diguanide. A few patients who had been on com-
bined therapy were initially tried on HB419 alone, but in
no case was this successful, and so it was decided there-
after to continue with the diguanide at the same dose.
Patients were seen 2 - 4 weeks after starting HB419 and
then at monthly intervals. At each attendance the patient
was weighed with coat removed and was questioned about
symptoms and about urine tests performed at home.
Several of the more intelligent kept home records on
specially printed sheets. Blood was drawn for sugar esti-
mation and several other tests. All subjects had repeated
estimations of haemoglobin, total white cells and plate-
lets, blood urea, serum bilirubin, SGOT and alkaline
phosphatase. Early morning urine specimens brought to
clinics at' each visit were tested for sugar and protein by
ourselves.
Most patients were observed on HB419 for 5 - 6
months, some up to 10 months. In 3 cases failure was
evident after one month and insulin had to be started.
The maximum or final number of tablets of HB419 used
was as follows: 1 daily in 5 cases; 2 daily in 20 cases;
3 daily in 3 cases and 4 daily in 5 cases. One patient re-
quired none.
Patients were not considered 'failed' until a diguanide
had been used in conjunction with sulphonylurea (except
in one case when severe symptoms including weakness
and drowsiness developed).
RESULTS
Control was judged by the urine tests done by the
patients themselves and at the clinics, together with blood-
sugar readings taken in the clinic. 'Excellent', 'good' and
'fair' control are terms used as on the maker's test sheets.
Thus 'excellent' implies fasting blood-sugar levels below
120 mg./ lOO m!' (Autoanalyzer, Hoffman method) or
postprandial levels below 160 mg./ lOO ml. with no, or
almost no, glycosuria. 'Fair' indicates fasting levels be-
tween 150 and 200 mg. / 100 ml. with frequent glycosuria
of moderate degree. 'Good' is between these two.
It should be noted that, especially in older diabetics,
the blood-sugar level may be high when glycosuria is
absent, because of a high renal threshold. In such cases
we have estimated control' rather on the basis of the
blood-sugar levels, though to maintain really good con-
trol with high renal threshold is usually quite impossible
or at least impracticable.
The final judgement as regards control is shown in
Table I.
)
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CASE REPORTS
Casel
A White woman aged 66 years, who had been diabetic for
8 years and had been on sulphonylureas since diagnosis, was
well controlled on chlorpropamide plus phenformin, but com-
plained of severe flushing and palpitation after taking a small
tot of alcohol." On substituting HB4l9 for the chlorpropamide
this complaint was abolished.
Case 2
A thin White woman aged 55 years, recently diagnosed as
diabetic, initially required one tablet (250 mg.) of chlorpropa-
mide for control, and showed glycosuria after discontinuing
this. She was equally well controlled on a tablet of HB4l9,
though she said she felt queer and had to draw a deep breath
4 hours after taking it (? mild hypoglycaemia). The dose was
reduced to half a tablet and eventually the HB4l9 was with-
drawn, with a continuation of excellent control.
This patient illustrates the fact that recent diabetes may
initially need sulphonylurea for control, but subsequently may
be controlled quite well without any therapy except a diabetic-
type diet, even if the patient is not overweight."
Casel
A White woman aged 39 years, of normal weight and a
diabetic for 3 years, was taking lente insulin up to 60 units
daily and was irregularly controlled, going frequently from
hypoglycaemic reactions to gross glycosuria. Control became
'excellent' on only one tablet of HB419 daily, with no insulin.
Case 4
A Bantu man, aged 45 years and of normal weight, was
admitted to hospital in hyperosmolar, non-ketotic diabetic
coma.' After recovery he was controlled very well on
chlorpropamide 2 tablets plus phenformin 3 capsules daily. He
remained equally well controlled ('excellent') when 2 tablets
of HB4l9 were taken in place of the chlorpropamide.
DISCUSSION
HB419 appears to be a well-tolerated drug, approximately
equal to chlorpropamide in its ability to control diabetes,
tablet for tablet (i.e. 250 mg. chlorpropamide and 5 mg.
HB419). Because of the lack of toxicity of the compara-
tively minute dose of HB419, more than 2 tablets can be
given with impunity, and occasionally with improved re-
sults. Thus we thought that in 2 subjects the larger dose
of 4 tablets produced a distinctly better response than 2
tablets a day. Three cases seemed better controlled on
HB4l9 than on chlorpropamide, and in one the reverse
was the case. HB419 appeared to be distinctly more
powerful than tolbutamide or glymidine (Glycodiazine).8
HB419 combines well with the diguanides. It was pos-
sible to save about half the patients who were 'failing' on
sulphonylurea alone, including HB4l9, by adding a di-
guanide. Thus 8 of 17 cases became 'good' or 'excellent'
and another 5 became 'fair'.
'Excellent plus good' results were obtained in 60% of
the patients (20 out of 33). This seems quite reasonable
in view of the type of subjects selected for the trial. The
results were not markedly poorer in patients whose dia-
betes had been present for over 10 years, though there
were 4 failures out of 9 in this group.
The very small dose of HB419 required for control
would seem to be an advantage and hould reduce or
entirely eliminate the serious toxic effects that have been
occasionally described with other oral sulphonylureas.
In one of our cases sensitivity to alcohol was abolished on
changing from chlorpropamide to HB419; another patient
vomited when put on chlorpropamide but was able to
tolerate HB419 without any side-effects.
Some side-effects must, however, be expected, ince
they occur al 0 with placebos. Similarly it must be realized
that a placebo will lead to 'good control' of diabetes in
some 25% of new cases,'· but that this placebo effect is
eliminated when one drug is compared against another.
as in this present trial.
It must be understood that this report is concerned with
short-term therapy and no mention is made of secondary
failure of HB419. This has not yet been encountered,
though it is presumably to be expected later. On the other
hand, a longer trial may produce better results, since
some patients still in the trial may obtain improved con-
trol on higher doses of HB419 and/ or on combination
with diguanides where this has not yet been attempted.
SUMMARY
HB4l9 is a remarkably potent sulphonylurea, of which only a
few milligrams are effective in sensitive maturity-onset diabetics.
In a preliminary trial with 34 patients it appeared readily
acceptable, non-toxic and at least as potent as chlorpropamide.
It combined well with a diguanide where this was necessary.
Other workers have found that hypoglycaemia is a risk that
must be taken into account.
We should like to thank the Department of Chemical
Pathology, University of Cape Town (Pro!. J. Kench), who
performed the biochemical estimations; Mr M. S. Conradie of
the Haematology Service, Groote Schuur Hospital, who per-
formed the haematological studies (with kind permission of
Or R. S. Mibashan); Or J. G. Burger, Medical Superintendent
of Groote Schuur Hospital, for facilities; and our patients and
the nursing and secretarial staff for making this study possible.
We also wish to thank Messrs Hoechst Pharmaceuticals (Pty)
Ltd for financial support and for supplies of HB419 and
pharmacological data concerning it, and in particular Or R.
Muller and Mr G. Wintemitz.
This work was supported by the South African Council for
Scientific and Industrial Research and forms part of the
work of the joint University/CSIR Endocrine Research Group.
ADDENDUM
Secondary failure of HB4l9 occurred in one Coloured female
after one year's successful therapy, but good control was again
achieved by the addition of phenformin (Insoral TO).
A White female of 55 years was found to require only t
tablet of HB4l9 to produce good control, glycosuria recurring
if this was omitted.
At a conference on this drug (Tegemsee-Konferenz iiber das
neue orale Antidiabetikum HB4l9), held in January 1969, at
which results in some 6,000 cases were reported, it became
clear that the danger of hypoglycaemia is quite considerable.
Great care must be taken in starting treatment in very mild
diabetics, particularly in elderly patients.
Apart from hypoglycaemia and various side-effects that may
also be seen with placebos, the only adverse reaction definitely
attributable to the drug was a very occasional skin rash of
sensitivity type.
It was generally agreed that, apart from the natural risk of
hypoglycaemia, HB4l9 is a very safe and well-tolerated drug,
with approximately the same power as chlorpropamide for con-
trolling maturity-onset diabetics.
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